A 24-week , double-blind, randomized, parallel-group study of remogliflozin in patients with type 2 diabetes
Latest Information Update: 23 Jul 2020
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Jul 2020 New trial record
- 16 Jun 2020 Primary endpoint (change in HbA1C from baseline) has not been met.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association